Infectious diseases company Pneumagen (Holdings) Ltd on Wednesday announced GBP4m in investment led by Thairm Bio, Scottish Investment Bank (SIB) to progress the company's lead candidate, Neumifil into a clinical trial for COVID-19.
Neumifil is a first-in-class Carbohydrate Binding Modules (mCBMs), generated using Pneumagen's proprietary GlycoTarge platform. It is being developed for the universal treatment of respiratory tract infections (RTIs) caused by Influenza Virus and Respiratory Syncytial Virus and now coronaviruses including SARS-CoV-2, the cause of COVID-19.
The investment follows exciting data from Pneumagen's pre-clinical studies in COVID-19 using plaque reduction assays. The testing conducted at Public Health England's (PHE) Porton facility and from the University of Glasgow's MRC Centre for Virus Research, demonstrated efficacy in inhibiting SARS-CoV-2 infection.
(USD1=GBP0.82)
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib